ProCE Banner Activity

What Is “Severe” COVID-19, and Are the Immunocompromised at Greater Risk?

Clinical Thought
Here are my thoughts on how developing data may help you assess immunocompromised patients’ risk of severe COVID-19 illness.

Released: June 10, 2021

Expiration: June 09, 2022

Share

Faculty

Christopher J. Lehmann

Christopher J. Lehmann, MD

Fellow Physician
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago Medicine
Chicago, Illinois

Gregory Olson

Gregory Olson, MD

Clinical Instructor
Fellow

Department of Infectious Diseases
University of Chicago Medical Center
Chicago, Illinois

Renslow Sherer

Renslow Sherer, MD

Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Christopher J. Lehmann, MD

Fellow Physician
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago Medicine
Chicago, Illinois

Christopher Lehmann, MD, has no relevant conflicts of interest to report.

Gregory Olson, MD

Clinical Instructor
Fellow

Department of Infectious Diseases
University of Chicago Medical Center
Chicago, Illinois

Gregory Olson, MD, has no relevant conflicts of interest to report.

Renslow Sherer, MD

Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Renslow Sherer, MD, has no relevant conflicts of interest to report.